Introduction
============

Lung cancer remains a leading cause of cancer-related death, with 5-year survival rates of \<15%[@B1]. These malignancies can be classified as either non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC), although the former accounts for approximately 85% of cases[@B2]. Unfortunately, about 24% of NSCLC are diagnosed at an early stage (local disease, stage I or II), whereas 67% are diagnosed at more advanced stages (III and IV)[@B3]. Delayed diagnosis of lung cancer leads to increased mortality; patients diagnosed at an early stage (I or II) have a survival rate of 71%, compared with \<2% for patients with stage IV disease at diagnosis[@B4].

Asymptomatic patients whose pulmonary nodules were detected incidentally by computed tomography (CT) screening present a challenge to clinicians in terms of determining the characteristics of nodules and providing timely and necessary management. However, screening is associated with increased rates of misdiagnosis, as well as the administration of excessive treatment and wasted medical resources[@B5]. Therefore, suitable and convenient biomarkers are needed for the differential diagnosis of lung cancer. Although low-dose spiral CT has been recommended as a screening measure for high-risk patients according to the clinical guidelines of the National Comprehensive Cancer Network[@B6], the clinical value of this modality is limited by high costs and the extremely high false-positive rate (\~94.5%)[@B7]. Serum biomarkers, such as carcinoembryonic antigen (CEA), cancer antigen (CA)-125, and cytokeratin 19 fragments (Cyfra 21-1), have been used in clinical practice according to the guidelines of the National Academy of Clinical Biochemistry[@B8]. However, these serum markers have low levels of sensitivity (50-60%), despite high specificities (\~90%), and cannot meet the requirements of clinical practice[@B9]\][@B10]. Therefore, more effective and convenient biomarkers remain desirable.

Vascular endothelial growth factor (VEGF), which correlates strongly with abnormal angiogenesis[@B11], has been shown to play a critical role in lung cancer[@B12], and previous studies have applied VEGF to differential diagnoses among patients with chronic obstructive pulmonary disease and lung cancer, benign and malignant pleural fluid[@B13]. Notably, for patients with solitary pulmonary masses detected by chest radiography or CT screening, the levels of VEGF and sVEGFR-1 in bronchoalveolar lavage fluid facilitate the differential diagnosis of primary lung cancer[@B14]. However, to the best of our knowledge, few studies has evaluated the application of serum VEGF to the differential diagnosis of patients with pulmonary nodules from early-stage NSCLC.

A major advance in recent years has been the identification of epithelial growth factor receptor (EGFR) as a driver of disease progression and a therapeutic target in a subgroup of NSCLC patients[@B15][@B16]. Approximately 40-50% of lung adenocarcinomas in Asian populations have *EGFR* mutations, and less than 10% of other NSCLC have *EGFR* mutations[@B17]. It was reported that *EGFR* mutations were related to the expression of VEGF in tumor tissue[@B18], but there are no reports on the association between *EGFR* mutations and level of VEGF in peripheral blood in NSCLC.

In this study, we evaluated whether VEGF could serve as a reliable marker for the differential diagnosis and severity assessment of NSCLC. Accordingly, we compared the serum levels of VEGF, CEA, CA-125, and Cyfra 21-1 between patients with NSCLC and those with benign pulmonary nodules (BPN), as well as healthy controls (HC), and evaluated the diagnostic sensitivities and specificities of these serum indexes alone and in combination. Additionally, we analyzed the relationship between VEGF and EGFR mutations/BPN size. Finally, we compared VEGF levels by TNM stage, malignancy grade, and pro- or post-surgical status.

Methods
=======

Patients and sample collection
------------------------------

We consecutively enrolled 180 patients with NSCLC, 136 patients with BPN, and 119 HC. Serum samples from all subjects were collected at Sun Yat-Sen University Cancer Center.

Patients with NSCLC were included if they met the following criteria: confirmation of NSCLC via a review of pathologic slides by two independent observers to classify the histologic subtype; no pro-surgical or pro-diagnostic history of anti-neoplastic therapy, radiotherapy, or chemotherapy; the absence of a second carcinoma, as determined from the clinical history, computed tomography (CT), ultrasonographic examination, and routine laboratory tests; and a post-surgical serum sample (collected from December 2014 to February 2016). Additionally, some patients contributed serum samples both before and within 25-30 days after surgery. The characteristics of the NSCLC patients are presented in Table [1](#T1){ref-type="table"}.

Patients with BPN were identified via CT screening and subsequently monitored for 2 years using CT, with no evidence of nodule growth and no clinical diagnosis of cancer. None had a history of previous cancer or chemotherapy. HC were subjects who had not received a diagnosis of malignant or benign tumors after routine examinations, including CT, ultrasonographic examination, and routine laboratory tests. Serum samples were collected from patients with BPN and HC between December 2014 and August 2015. The baseline characteristics of patients with BPN and HC are presented in Table [2](#T2){ref-type="table"}.

Primary tumor samples were obtained from some of the patients. We collected the following clinicopathologic data for each NSCLC patient: age, gender, malignant grade, and pathologic TNM stage. Clinical stage was assessed according to the 7th edition of the Lung Cancer Staging International Division guidelines, which were published by the Union for International Cancer Control and the International Association for the Study of Lung Cancer in 2009. NSCLC was defined based on CT findings and confirmed by histopathology, according to the World Health Organization Classification of Tumors of the Lung. All patients provided written informed consent for their medical information to be stored and used in the hospital database at their first visit to our center. This study was agreed to be conducted by the Institutional Review Board and Human Ethics Committee of Sun Yat-Sen University Cancer Center through the review.

DNA extraction
--------------

DNA was extracted from the 10-mm thick tumor tissue sections microdissected from formalin-fixed paraffin-embedded surgically resected tumor specimens. To obtain genomic DNA, the QiAmp DNA Mini kit (Qiagen, Hilden, Germany) was used according to the manufacturer\'s instructions.

Scorpions amplification refractory mutation system (ARMS) for the detection of *EGFR* mutations
-----------------------------------------------------------------------------------------------

We used the EGFR Scorpions kit (DxS, Manchester, UK), which combines two technologies, ARMS and Scorpions, to detect mutations in real-time polymerase chain reaction (rt-PCR) reactions. All reactions were performed according to the manufacturer\'s instructions. Real-time PCR was performed with the ABI PRISM 7700 sequence detector (Applied Biosystems, Foster City, CA, USA) under the following conditions: initial denaturation at 95 °C for 10 minutes, 40 cycles of 95 °C for 30 seconds, and 61 °C for 60 seconds with fluorescence reading at the end of each cycle. The data were analyzed with SDS2.0 software (Applied Biosystems) according to the manufacturer\'s instructions.

DNA sequencing for the detection of *KRAS* mutations
----------------------------------------------------

DNA amplification was performed using a Techne TC-512 PCR System (Techne, Cambridge, UK). The PCR cycling conditions consisted of an initial denaturation step at 95 °C for 5 minutes, followed by 35 cycles of 95 °C for 40 seconds, 56 °C for 30 seconds, 72 °C for 30 seconds, and a final extension step at 72 °C for 6 minutes. The PCR products were separated by electrophoresis in a 2% agarose gel. The product was excised from the gel and purified with an AxyPrep^TM^ DNA Gel Extraction Kit (Axygen Biosciences, Union City, CA, USA) following the manufacturer\'s instructions. The purified PCR products were reamplified by a BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) with both primers. The products were sequenced in both directions using the ABI Prism 3700 Analyzer (Applied Biosystems).

Fluorescent in situ hybridization (FISH) analysis of anaplastic lymphoma kinase (ALK) rearrangements
----------------------------------------------------------------------------------------------------

Bacterial artificial chromosomes, RP11-667I6 and RP11-100C1 (Children\'s Hospital Oakland Research Institute), were used as break-apart probes for the *EML4* and *ALK* genes, respectively. Bacterial artificial chromosome DNA was labeled with either spectrum red 2-deoxyuridine, 5-triphosphate (dUTP) or spectrum green 11-dUTP by nick translation (Vysis) according to the manufacturer\'s recommendations. Slides for metaphase FISH from the cell lines were prepared using standard cytogenetic methodologies. The probes were hybridized and washed according to standard FISH procedures. A positive FISH result for *ALK* rearrangement was defined as \>15% of tumor cells with a split signal and was confirmed by immunohistochemistry.

Analysis of VEGF levels
-----------------------

Serum VEGF levels were determined using a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA; WEGO Biology, Weihai, China) according to the manufacturer\'s instructions. Briefly, 50 μl of each serum sample was added per well, followed by 50 μl of a horseradish peroxidase-conjugated detection antibody, after which the reaction was incubated for 1 h at 37 ºC. Next, the wells were washed five times with 1X washing buffer, and incubated with an enhanced chemiluminescent agent in the dark for 3 min at 18-25 ºC. Finally, the chemiluminescence values were detected using a chemiluminescence immunity analyzer (BK-L96C, Zhongshengbaike, Beijing, China).

Analysis of tumor markers
-------------------------

An Elecsys immunoassay analyzer (COBAS-E-602; Roche, Shanghai, China) was used to analyze levels of the tumor markers CEA, CA-125, and Cyfra 21-1.

Specimen characteristics
------------------------

All the peripheral blood samples were collected in anticoagulant-free tubes and processed according to standard protocols. Within 30 minutes of collection, the blood samples were centrifuged at 3,000 rpm at room temperature for 10 min. Subsequently, the supernatants were divided into 200-µl aliquots and stored at -80 ºC until testing.

Statistical Analysis
--------------------

The statistical analysis was performed using SPSS 20 software (SPSS, Inc., Chicago, IL, USA). The frequency distributions of analytes are presented as means ± standard errors of the means. Comparisons of VEGF, Cyfra 21-1, CA125, and CEA levels among the three groups were made using the Kruskal-Wallis (K-W) test with the Bonferroni correction for multiplicity. The Mann-Whitney (M-W) U test was used to analyze differences in VEGF levels according to pathological parameters (e.g., age, gender, T/M/N stage). Differences between pro- and post-surgical VEGF levels were evaluated using the Wilcoxon matched-pairs signed-rank test. Differences in baseline characteristics were assessed using the chi-square test.

To evaluate the diagnostic abilities of the selected biomarkers, area under the receiver operating characteristic (ROC) curve (AUC) values were determined for the indicated patient groups, and the specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV), and Youden\'s index were calculated for biomarkers\' cut-off levels. Sensitivity was calculated as the true positive rate/(true positive + false negative rate), and specificity was calculated as the true negative rate/(true negative + false positive rate). PPV was calculated as the true positive rate/(true positive + false positive rate), and NPV was calculated as the true negative rate/(true negative + false negative rate). Youden\'s index values were calculated as the (sensitivity + specificity)-100, and the highest values were set as the cut-off values. Differences were considered significant at a *P* value \<0.05.

Results
=======

We recruited a total of 435 participants (NSCLC, 180; BPN, 136; HC, 119) for whom the characteristics are summarized in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. The VEGF levels of each subgroup and the corresponding *P* values are listed in Table [1](#T1){ref-type="table"}.

VEGF serum levels in patients with NSCLC or BPN and healthy controls
--------------------------------------------------------------------

In an ELISA analysis of the serum VEGF levels of each participant, we determined a median serum VEGF level of 146.23 ± 95.11 pg/ml among patients with NSCLC, which was significantly higher than the levels observed in patients with BPN (41.15 ± 24.56 pg/ml, *P* \<0.0001, M-W test, Fig. [1](#F1){ref-type="fig"}a) and HC (35.90 ± 23.49 pg/ml, *P* \<0.0001, M-W test, Fig. [1](#F1){ref-type="fig"}a). We additionally analyzed the association between the serum VEGF levels and the clinical characteristics of patients with NSCLC, and found that patients with stage T3-T4 disease had a significantly higher median serum VEGF level (212.2 ± 104.3 pg/ml), compared to patients with stage T0-T2 disease (126.3 ± 114.8 pg/ml; *P* \<0.0001, Table [1](#T1){ref-type="table"}). In addition, we observed associations between serum VEGF levels and malignancy grade, N stage, M stage, and TNM stage (Table [1](#T1){ref-type="table"}, Fig. [2](#F2){ref-type="fig"}). However, we did not observe obvious relationships between serum VEGF levels and other patient characteristics, such as age, gender, or type of cancer.

ROC analyses of the diagnostic efficacies of VEGF, CEA, CA125, and Cyfra 21-1 and the construction of diagnostic models for NSCLC
---------------------------------------------------------------------------------------------------------------------------------

Next, we plotted ROC curves based on the ELISA results to determine the diagnostic effectiveness of the serum VEGF levels for distinguishing NSCLC from BPN and HC, and included the existing clinical biomarkers, CEA, CA125, and Cyfra 21-1, for comparison (Fig. [3](#F3){ref-type="fig"} A, B, Table [3](#T3){ref-type="table"}). The levels of the individual markers and their predictive values and likelihood ratios in the diagnosis of NSCLC are summarized in Table [3](#T3){ref-type="table"}. We used a binary logistic regression to investigate whether diagnostic accuracy could be improved by combining the markers. Notably, the combination of VEGF, CEA, CA125, and Cyfra 21-1 improved the capacity for discrimination and yielded a better optimal diagnostic efficacy for patients with NSCLC \[AUC: NSCLC vs. HC = 0.921 (0.890-0.952) and NSCLC vs. BPN = 0.916 (0.882-0.949), Table [3](#T3){ref-type="table"}, compared with VEGF alone.

Because early diagnosis can significantly improve the 5-year overall survival, we analyzed the role of VEGF in early diagnosis. VEGF had the best diagnostic efficacy among the four biomarkers \[AUC: NSCLC vs. HC = 0.747(0.641-0.781) and NSCLC vs. BPN = 0.765 (0.697-0.833), Fig. [4](#F4){ref-type="fig"} A, B, Table [5](#T5){ref-type="table"}\], and the combination of VEGF, CEA, CA125, and Cyfra 21-1 improved the capacity for discrimination and yielded a better optimal diagnostic efficacy for patients with NSCLC \[AUC: NSCLC vs. HC = 0.872 (0.822-0.923) and NSCLC vs. BPN = 0.869(0.818-0.921), Fig. [4](#F4){ref-type="fig"} A, B, Table [5](#T5){ref-type="table"}\], compared with VEGF alone.

The size of benign pulmonary nodules did not affect the level of serum VEGF significantly
-----------------------------------------------------------------------------------------

We divided patients with BPN into two groups based on the size of the nodules: group 1 length\*width ≤ 25 mm^2^ and group 2 \>25 mm^2^. Then, we compared the level of VEGF of the two groups (Fig. [5](#F5){ref-type="fig"}). The difference in VEGF level between the groups was not significant (*P* = 0.860).

*EGFR* mutations did not affect the level of serum VEGF significantly
---------------------------------------------------------------------

As *KRAS* and *ALK* are downstream of EGFR, we excluded all the case with *KRAS* mutations or *ALK* rearrangements. There was no significant difference in VEGF levels between the *EGFR* mutations group and the wild-type group (*P* = 0.187, Fig. [6](#F6){ref-type="fig"} A). Mutations associated with enhanced sensitivity to EGFR TKIs are found in exons 18-21 of the TK domain of *EGFR*^\[19\[20\]^. Two types of mutations---short in-frame deletions in exon 19, clustered around the amino-acid residues 747-750, and a specific exon 21 point mutation (L858R)---have been reported to comprise up to 90% of all activating *EGFR* mutations[@B21]. Therefore, we divided the cases into two groups: exon 19 mutations and exon 21 mutations. Next, we compared these groups with the *EGFR* wide-type group (Fig. [6](#F6){ref-type="fig"} B). There were no significant differences in VEGF level among the groups. The *P* value between the exon 21 mutation and the wide-type group was 0.091.

Elevated serum VEGF levels before surgery, compared with after surgery
----------------------------------------------------------------------

We collected both pro- and post-surgical (25-30 days after surgery) serum samples from 16 patients with NSCLC. The post-surgical samples had significantly lower VEGF levels compared to the pro-surgical samples (124.0 ± 87.5 vs. 87.7 ± 30.5 pg/ml, *P* = 0.0041, Fig. [2](#F2){ref-type="fig"} F).

Discussion
==========

The distinction of malignant lung tumors from BPN is a basic problem in the field of respiratory disease. Although imaging techniques such as CT have facilitated the detection of early-stage lung cancers, such analyses are expensive and yield excessively high false positive rates (\>95%)[@B22]. Other diagnostic techniques, such as bronchial microscopy (e.g., bronchoalveolar lavage, biopsy, and needle biopsy) are available, but these are invasive and risky, yield only moderate sensitivity (65-79%), and have a small scope of application[@B23]. By contrast, peripheral blood collection is noninvasive, and could be applied to the differential diagnosis of BPN and malignant lung tumors. To date, many serological tumor markers have been used to diagnose cancer, including prostate-specific antigen for prostate cancer, and alpha-fetoprotein for liver cancer^\[24\[25\]^. However, the currently available clinical biomarkers of lung cancer, Cyfra 21-1, CEA, and CA125 do not have optimal sensitivity and specificity. Accordingly, biomarkers with better diagnostic efficiencies are urgently needed.

Tumor growth depends on angiogenesis[@B26], a process involving the interactions of many angiogenic and inhibitory factors[@B27]. In this context, VEGF specifically promotes endothelial cell proliferation and induces angiogenesis[@B28], and its biological effects include increasing vascular permeability, promoting endothelial cell mitosis, and affecting the extracellular matrix. VEGF can also induce the expression of plasminogen activator and its inhibitors, as well as tissue factors and matrix collagenase, which are conducive to vascular growth[@B29]. As Dvorak et al.[@B30] reported, the abnormal proliferation of tumor cells leads to a hypoxic environment conducive to VEGF production. In turn, VEGF specifically acts on vascular endothelial cells to promote cellular proliferation, migration, and angiogenesis. In summary, VEGF plays an important role in vascular growth.

Tamura et al.[@B31] reported significant correlations of serum levels of VEGF with tumor levels of VEGF and microvessel density in patients with NSCLC. Although VEGF is also present in normal tissues, it is only expressed at very low levels under very specific circumstances. Accordingly, serum VEGF levels are likely somewhat reflective of tumor angiogenesis, leading us to our hypothesis that this biomarker could be used to distinguish benign from malignant lung nodules. Serum VEGF levels were also reported to be useful in the diagnosis of various other cancers, including breast, stomach, and colorectal cancer[@B32]. In addition, SG Liu et al. [@B33]detected serum VEGF levels in healthy individuals and patients with benign pulmonary diseases and NSCLC; here, only 37(46.3%) NSCLC was stage I/II, and the diagnostic effect of VEGF in early-stage NSCLC was not shown. Fifteen of the 40 cases of benign lung disease were inflammatory pseudotumors, and the remainder comprised 14 acute exacerbations of chronic bronchitis, 8 acute attacks of bronchitis asthma, and 3 pulmonary interstitial fibrosis cases. The most difficult problem was identifying early-stage, rather than advanced-stage, NSCLC from BPN. In our study, VEGF performed well in distinguishing early-stage NSCLC from BPN and HC. As reported[@B34], most cases of BPN are inflammatory pseudotumors, followed by carcinoid and pulmonary tuberculosis. Therefore, we collected additional samples from patients with BPN to further prove the differential diagnostic efficiency of serum VEGF for benign and malignant nodules.

*EGFR* mutations are closely related to the generation and treatment of lung adenocarcinoma. It has been reported that there is a correlation between the expression of VEGF and *EGFR* mutations[@B35]. However, these reports examined VEGF at transcription and protein levels in tumor tissues and did not address the association between *EGFR* mutation and peripheral blood VEGF. Based on our current results, *EGFR* mutations are not significantly associated with serum VEGF levels.

Our findings indicate that for NSCLC diagnosis, VEGF was more effective than known clinical serological markers. However, the addition of these markers to VEGF led to a model with an increased diagnostic efficacy. Additionally, we found that the VEGF levels were associated with TNM stages and tumor malignancy grade, independent of age, gender, and type of cancer. We further observed a significant decrease in serum VEGF levels from pro- to post-surgery. Taken together, our findings suggest that the serum VEGF levels could be used as a diagnostic biomarker, as well as an indicator of lung cancer prognosis and treatment efficacy.

In summary, our findings suggest that the serum VEGF levels could facilitate the differential diagnosis of NSCLC from BPN. Furthermore, the serum VEGF levels could be used to assess both prognosis and the curative effect.
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![**Elevated serum levels in serum samples from patients with NSCLC and controls.** Serum levels of VEGF (A), Cyfra 21-1 (B), CEA (C), and CA-125 (D) in HC (n = 119), patients with BPN (n = 136), and NSCLC (n = 180). \*\*\* *P* \<0.0001. NS, nonsense; HC, healthy controls; BPN, benign pulmonary nodules; NSCLC, non-small cell lung cancer; VEGF, vascular endothelial growth factor; Cyfra 21-1, cytokeratin 19 fragments; CEA, carcinoembryonic antigen; CA-125, cancer antigen 125](jcav09p1538g001){#F1}

![**Serum VEGF levels are associated with T, N, M and TNM stages, malignant grades, and surgery.** Comparisons of VEGF levels in T0-2 (n = 145) vs. T3-4 (n = 29) (A), N0 (n = 107) vs. N1-3 (n = 63) (B), M0 (n = 146) vs. M1 (n = 34) (C), and TNM stage I-II (n = 114) vs. III-IV (n = 66) (D) cases, malignant grades 1-2 (n = 70) vs. 3 (n = 53) (E), and pro- vs. post-surgical serum samples (n = 16). \*\* *P* \<0.01. VEGF, vascular endothelial growth factor; T, tumor; N, lymph node involvement; M distant metastasis; G, malignancy grade; pro-sur, pro-surgical serum; post-sur, post-surgical serum](jcav09p1538g002){#F2}

![**Ability of a combination of VEGF, CEA, CA-125, and Cyfra 21-1 to distinguish between NSCLC and HC/BPN.** Comparison of ROC curves of VEGF, CEA, CA-125, Cyfra 21-1, and a combination thereof between NSCLC cases and HC (A) and between NSCLC and BPN (B). ROC, receiver operating characteristic; VEGF, vascular endothelial growth factor; Cyfra 21-1, cytokeratin 19 fragments; CEA, carcinoembryonic antigen; CA-125, cancer antigen 125; NSCLC, non-small cell lung cancer; BPN, benign pulmonary nodules; HC, healthy controls](jcav09p1538g003){#F3}

![**Ability of a combination of VEGF, CEA, CA-125, and Cyfra 21-1 to distinguish between early stage NSCLC and HC/BPN.** Early stage NSCLC including stage I and II.](jcav09p1538g004){#F4}

![**The size of benign pulmonary nodules did not affect the level of serum VEGF significantly.** Group1 length\*width ≤ 25mm^2^ and Group 2 \>25mm^2^.](jcav09p1538g005){#F5}

![EGFR mutations did not affect the level of serum VEGF significantly.](jcav09p1538g006){#F6}

###### 

Level of serum VEGF and clinical characteristics of patients with NSCLC

  ------------------------------------------------------------------------------
  Characteristics   Case numbers   Percentage   VEGF(pg/ml)\         *P* Value
                                                Median(range)        
  ----------------- -------------- ------------ -------------------- -----------
  Age, years                                                         

  \<60              77             42.78        151.2(0.1-880.0)     0.300

  ≥ 60              103            57.22        136.5(6.1-868.8)     

  Gender                                                             

  Male              103            57.22        153.6(0.1-880.0)     0.353

  Female            77             42.78        128.5(6.1-694.2)     

  Type                                                               

                    155            86.11        130.8(0.1-868.8)     0.254

                    11             6.11         209.3(53.3-694.2)    

                    3              1.67         152.2(139.3-170.7)   

                    6              3.33         227.1(94.8-605.7)    

                    3              1.67         150.8(114.9-222.5)   

                    2              1.11         287.1(106.5-467.7)   

  Grade                                                              

  1                 5              2.78         50.4(15.6-108.4)     \<0.0001

  2                 65             36.11        90.2(6.1-313.4)      

  3                 53             29.44        169.5(0.1-694.2)     

  x                 57             31.67        181.4(0.1-467.7)     

  T stage                                                            

  T0                3              1.67         35.7(12.0-81.4)      \<0.0001

  T1                80             44.44        100.3(7.2-511.3)     

  T2                62             34.44        164.2(0.1-868.8)     

  T3                18             10.00        284.0(163.7-605.7)   

  T4                11             6.11         162.2(92.4-467.7)    

  x                 6              3.33         309.2(159.3-880.0)   

  N stage                                                            

  N0                107            59.44        101.5(0.1-605.7)     \<0.0001

  N1                22             12.22        140.5(59.8-216.5)    

  N2                34             18.89        228.5(86.1-694.2)    

  N3                7              3.89         301.8(106.5-868.8)   

  x                 10             5.56         185.9(145.1-880.0)   

  M stage                                                            

  M0                146            81.11        119.0(0.1-605.7)     \<0.0001

  M1                34             18.89        263.1(16.1-880.0)    

  TNM status                       0.00                              \<0.0001

  Stage I           89             49.44        86.0(0.1-295.3)      

  Stage II          25             13.89        162.8(59.8-605.7)    

  Stage III         32             17.78        176.5(53.3-511.3)    

  Stage IV          34             18.89        289.3(92.4-880.0)    
  ------------------------------------------------------------------------------

A Kruskal-Wallis test.

###### 

The baseline of NSCLC, BPN and HC

  Characteristics   NSCLC   BPN   HC   *P* Value
  ----------------- ------- ----- ---- -----------
  Age, years                           
  \<60              77      75    53   0.074
  ≥ 60              103     61    66   
  Gender                               
  Male              103     76    58   0.327
  Female            77      60    61   

###### 

The diagnostic efficiency of models in differentiating NSCLC cases from BPN/HC

                              AUC (95% CI)         Cut-off value   SN (%)   SP (%)   PPV (%)   NPV (%)   Positive LR   Negative LR
  --------------------------- -------------------- --------------- -------- -------- --------- --------- ------------- -------------
  NSCLC vs. control                                                                                                    
  VEGF                        0.824(0.773-0.874)   79.3            75.0     93.3     94.4      71.6      11.2          0.268
  Cyfra 21-1                  0.692(0.632-0.752)   3.34            62.8     71.4     76.2      54.5      2.20          0.521
  CA125                       0.752(0.697-0.806)   13.7            64.4     77.3     81.0      41.4      2.84          0.460
  CEA                         0.763(0.709-0.816)   3.37            62.8     85.7     87.8      59.1      4.39          0.434
  VEGF+Cyfra 21-1+CA125+CEA   0.916(0.882-0.950)   0.519           85.0     90.0     92.7      79.9      8.43          0.167
  NSCLC vs. BPN                                                                                                        
  VEGF                        0.839(0.791-0.886)   78.7            75.0     95.6     95.8      74.7      17.0          0.262
  Cyfra 21-1                  0.739(0.709-0.801)   2.82            75.6     67.6     75.7      68.1      2.33          0.361
  CA125                       0.708(0.650-0.766)   10.9            78.3     61.0     72.1      65.9      2.01          0.356
  CEA                         0.745(0.691-0.798)   4.65            55.6     87.5     85.5      59.8      4.45          0.507
  VEGF+Cyfra 21-1+CA125+CEA   0.913(0.879-0.947)   0.488           84.4     91.9     93.3      81.7      10.4          0.170

Abbreviations: LR, likelihood ratio; NPV, negative predictive value; PPV, positive predictive value.

###### 

The baseline of early stage NSCLC, BPN and HC

  Characteristics   I/II   BPN   HC   *P* Value
  ----------------- ------ ----- ---- -----------
  Age, years                          
  \<60              48     75    53   0.085
  ≥ 60              66     61    66   
  Gender                              
  Male              63     76    58   0.464
  Female            51     60    61   

###### 

The diagnostic efficiency of models in differentiating early stage NSCLC from BPN/HC

                              AUC (95% CI)         Cut-off value   SN (%)   SP (%)   PPV (%)   NPV (%)   Positive LR   Negative LR
  --------------------------- -------------------- --------------- -------- -------- --------- --------- ------------- -------------
  NSCLC vs. control                                                                                                    
  VEGF                        0.747(0.641-0.781)   67.3            64.9     91.6     88.5      72.3      7.72          0.383
  Cyfra 21-1                  0.633(0.561-0.704)   3.34            54.4     71.4     65.6      61.0      1.90          0.639
  CA125                       0.667(0.597-0.736)   13.7            52.6     77.3     69.9      62.0      2.32          0.613
  CEA                         0.711(0.641-0.781)   4.48            54.4     93.3     89.0      67.2      8.09          0.489
  VEGF+Cyfra 21-1+CA125+CEA   0.872(0.822-0.923)   0.448           79.8     87.4     86.4      81.2      6.33          0.231
  NSCLC vs. BPN                                                                                                        
  VEGF                        0.765(0.697-0.833)   78.7            63.2     95.6     93.5      72.2      14.3          0.385
  Cyfra 21-1                  0.684(0.617-0.768)   3.22            59.6     75.0     70.5      65.0      2.39          0.538
  CA125                       0.620(0.551-0.690)   10.2            73.7     54.4     61.8      67.4      1.62          0.484
  CEA                         0.699(0.630-0.768)   5.50            46.5     94.9     90.0      63.9      9.03          0.564
  VEGF+Cyfra 21-1+CA125+CEA   0.869(0.818-0.921)   0.457           78.1     91.9     90.6      80.7      9.65          0.239

Abbreviations: LR, likelihood ratio; NPV, negative predictive value; PPV, positive predictive value.

###### 

The baseline of BPN

               Group 1   Group 2   *P* Value
  ------------ --------- --------- -----------
  Age, years                       
  \<60         38        36        0.685
  ≥ 60         34        28        
  Gender                           
  Male         39        37        0.669
  Female       33        27        
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